skip navigation

Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial

May 12, 2022


“This is a significant and exciting achievement for our company,” said Chief Operating Officer Cameron West, MD. “Our Phase 1 study demonstrated that 6.02 has a favorable safety profile and provided clinical benefit to patients. Based on this data, in addition to the robust preclinical data, we are optimistic that 6.02 in combination with capecitabine in patients with metastatic breast cancer may provide increased ¬†benefit over single-agent capecitabine.”¬†